Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (5): 928-931. doi: 10.19723/j.issn.1671-167X.2024.05.028
Previous Articles Next Articles
Dongwu LIU1, Jie CHEN2, Mingli GAO1, Jing YU1,*()
CLC Number:
1 |
Demirkan FG , Doǧan S , Kalyoncu Uçar A , et al. Systemic lupus erythematosus complicated with Castleman disease: A case-based review[J]. Rheumatol Int, 2021, 41 (2): 475- 479.
doi: 10.1007/s00296-020-04684-4 |
2 |
Minemura H , Tanino Y , Ikeda K . Possible association of multicentric Castleman' s disease with autoimmune lymphoproliferative syndrome[J]. Biores Open Access, 2018, 7 (1): 47- 51.
doi: 10.1089/biores.2017.0025 |
3 |
Tabata S , Higuchi T , Tatsukawa S , et al. Idiopathic multicentric Castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab[J]. Intern Med, 2019, 58 (22): 3313- 3318.
doi: 10.2169/internalmedicine.2989-19 |
4 | 中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42 (7): 529- 534. |
5 | 郑东辉, 莫颖倩, 戴冽, 等. 类风湿关节炎不同滑膜淋巴细胞分布类型的临床病理特点[J]. 中山大学学报(医学科学版), 2009, 30 (5): 571- 576. |
6 | 张玲玲, 魏伟. BAFF/BAFF-R通过PI3K/Akt/mTOR信号转导通路调节B淋巴细胞功能在类风湿关节炎发病机制中的意义[J]. 中国药理学通报, 2010, 26 (7): 847- 850. |
7 | Picemo V , Ferro F , Adinolfi A , et al. One year in riview: The pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2015, 33 (4): 551- 558. |
8 | 唐果, 龙丽, 韩雅欣, 等. 类风湿关节炎合并结核感染的临床特点及相关因素[J]. 北京大学学报(医学版), 2020, 52 (6): 1029- 1033. |
9 | 刘娣, 郭万珍, 蔡华聪, 等. 类风湿关节炎并发淋巴瘤的临床特征[J]. 中华临床免疫和变态反应杂志, 2015, 9 (4): 292- 296. |
10 |
Castleman B , Towne V . Case records of the Massachusetts General Hospital weekly clinicopathological exercises: Case 40011[J]. N Engl J Med, 1954, 250 (1): 26- 30.
doi: 10.1056/NEJM195401072500107 |
11 |
Wang HW , Pittaluga S , Jaffe ES . Multicentric Castleman disease: Where are we now?[J]. Semin Diagn Pathol, 2016, 33 (5): 294- 306.
doi: 10.1053/j.semdp.2016.05.006 |
12 |
Nguyen D , Diamond L , Hansmann N , et al. Castleman' s disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants[J]. Histopathology, 1994, 24 (5): 437- 443.
doi: 10.1111/j.1365-2559.1994.tb00552.x |
13 |
Herrada J , Cabanillas F , Rice L , et al. The clinical behavior of localized and multicentric Castleman disease[J]. Ann Intern Med, 1998, 128 (8): 657- 662.
doi: 10.7326/0003-4819-128-8-199804150-00010 |
14 | Peterson B , Frizzera G . Multicentric Castleman' s disease[J]. Semin Oncol, 1993, 20 (6): 636- 647. |
15 |
Frizzera G , Peterson BA , Bayrd ED , et al. A systemic lymphoproliferative disorder with morphologic features of Castleman' s disease: Clinical findings and clinicopathologic correlations in 15 patients[J]. J Clin Oncol, 1985, 3 (9): 1202- 1216.
doi: 10.1200/JCO.1985.3.9.1202 |
16 |
Bowne WB , Lewis JJ , Filippa DA , et al. The management of unicentric and multicentric Castleman' s disease: A report of 16 cases and a review of the literature[J]. Cancer, 1999, 85 (3): 706- 717.
doi: 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7 |
17 |
Nishimoto N , Kanakura Y , Aozasa K , et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease[J]. Blood, 2005, 106 (8): 2627- 2632.
doi: 10.1182/blood-2004-12-4602 |
18 |
Casper C , Voorhees PM , Fayad LE , et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman' s disease[J]. Blood, 2013, 122 (21): 1806.
doi: 10.1182/blood.V122.21.1806.1806 |
19 | de Marchi G , de Vita S , Fabris M , et al. Systemic connective tissue disease complicated by Castleman' s disease: Report of a case and review of the literature[J]. Haematologica, 2004, 89 (4): 7- 10. |
20 |
Jacobs SA , Vidnovic N , Patel H , et al. Durable remission of HIV-negative, Kaposi' s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate[J]. Clin Rheumatol, 2007, 26 (7): 1148- 1150.
doi: 10.1007/s10067-006-0272-8 |
21 | Sun Y , Wang D , Salvadore G , et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castle-man' s disease[J]. Brain Behav Immun, 2017, 66 (11): 156- 164. |
[1] | Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525. |
[2] | Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283. |
[3] | Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021. |
[4] | Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992. |
[5] | Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Correlation analysis between body mass index and clinical characteristics of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 993-999. |
[6] | Yin-ji JIN,Lin SUN,Jin-xia ZHAO,Xiang-yuan LIU. Significance of IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 antibody in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 631-635. |
[7] | Wen-xin CAI,Shi-cheng LI,Yi-ming LIU,Ru-yu LIANG,Jing LI,Jian-ping GUO,Fan-lei HU,Xiao-lin SUN,Chun LI,Xu LIU,Hua YE,Li-zong DENG,Ru LI,Zhan-guo LI. A cross-sectional study on the clinical phenotypes of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1068-1073. |
[8] | Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078. |
[9] | Rui LIU,Jin-xia ZHAO,Liang YAN. Clinical characteristics of patients with rheumatoid arthritis complicated with venous thrombosis of lower extremities [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1079-1085. |
[10] | Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Cross-sectional study on quality of life and disease activity of rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1086-1093. |
[11] | GAO Chao,CHEN Li-hong,WANG Li,YAO Hong,HUANG Xiao-wei,JIA Yu-bo,LIU Tian. Validation of the Pollard’s classification criteria (2010) for rheumatoid arthritis patients with fibromyalgia [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 278-282. |
[12] | ZHONG Hua,XU Li-ling,BAI Ming-xin,SU Yin. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031. |
[13] | LOU Xue,LIAO Li,LI Xing-jun,WANG Nan,LIU Shuang,CUI Ruo-mei,XU Jian. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025. |
[14] | LUO Liang,HUO Wen-gang,ZHANG Qin,LI Chun. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036. |
[15] | ZHANG Lu,HU Xiao-hong,CHEN Cheng,CAI Yue-ming,WANG Qing-wen,ZHAO Jin-xia. Analysis of cervical instability and clinical characteristics in treatment-naive rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1049-1054. |
|